Novavax CEO and leadership

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

Experienced CEO in biotechnology industry. Have developed multiple products from early start-up through Phase2/3 clinical trials in infectious disease, vaccines, with multiple rounds of financing from Series A through 2 IPO's and acquisitions.

Specialties: infectious disease, autoimmune disease, genetic disease, immunology

Mr. Lee is senior vice president and chief information officer with responsibility for leading the information technology operations, network infrastructure, enterprise applications, project management, and cybersecurity programs. He works closely with senior management to align IT investments with corporate strategy and business objectives. He joined Novavax in 2017 as senior director of IT with more than 20 years of IT experience, the vast majority of which has been in the life sciences industry. Prior to joining Novavax, he served as vice president of cloud solutions at IPDS, Inc., an information technology services company, where he led development and implementation of the cloud solutions portfolio. Mr. Lee previously held positions of increasing responsibility at Human Genome Sciences (HGS) leading up to its acquisition by GlaxoSmithKline (GSK). He led the global IT integration and successfully completed the disposition of all IT assets during the transition of HGS into GSK.

Dr. Smith is senior vice president of discovery and pre-clinical research and chief scientist, with responsibility for oversight of discovery, and managing scientific, technological and research operations at Novavax. Dr. Smith joined Novavax in January 2004 as vice president of vaccine development, where he oversaw the company's vaccine technology group. He led the development of Novavax’ core vaccine technology used in the development of nanoparticle vaccines for respiratory syncytial virus, influenza, Ebola, and coronaviruses, including SARS, MERS and SARS-CoV-2, which causes COVID-19. Previously, Dr. Smith was chief scientific officer at Protein Sciences Corporation, responsible for leading the scientific team that developed the first human immunodeficiency virus (HIV) vaccine candidate approved by the FDA for testing in the U.S., and the first recombinant influenza vaccine, Flublok™. He received his Bachelor of Science in biology from the University of North Dakota and a doctorate in microbiology from Texas A&M University.

• Credible advisor who understands the business and builds trust with other leaders

• Ability to manage ambiguity and to operate effectively when things are not certain or the path forward is unclear

• Skilled in building relationships, partnerships and working collaboratively at all levels of the organization

• Clear and demonstrated communication and coaching skills

• Strategic ability to drive creative organizational improvements and people decisions

• Demonstrated ability to analyze complex issues, evaluate difficult situations and effectively drive multiple teams on independent tracks simultaneously.

• Proven leadership in development of an HR team and providing effective innovative and competitive programs

Experienced CEO in biotechnology industry. Have developed multiple products from early start-up through Phase2/3 clinical trials in infectious disease, vaccines, with multiple rounds of financing from Series A through 2 IPO's and acquisitions.

Specialties: infectious disease, autoimmune disease, genetic disease, immunology